Aquestive insider reports zero common shares

Q: What does Aquestive Therapeutics (AQST) Form 3 show for Thomas A. Zalewski?

The Form 3 shows Chief Legal Officer Thomas A. Zalewski as a reporting person at Aquestive Therapeutics, Inc.. It reports a holding entry in common stock with 0 shares beneficially owned directly following the reported entry.

Q: How many Aquestive Therapeutics (AQST) common shares does the CLO report on Form 3?

The filing reports that Chief Legal Officer Thomas A. Zalewski beneficially owns 0 shares of Common Stock directly following the reported holding entry. No purchase, sale, acquisition, or disposition amounts are shown in this data.

Q: What ownership type is reported for the AQST Chief Legal Officer on Form 3?

The Form 3 data classifies Chief Legal Officer Thomas A. Zalewski as holding direct ownership, using ownership code D. Following the reported holding entry, direct beneficial ownership in common stock is listed as 0 shares.

Q: Are there any derivative securities reported for AQST’s Chief Legal Officer on Form 3?

The derivative section for this Form 3 is empty. The derivativeSummary shows no derivative positions, and the only security title reported in the provided data is Common Stock with total shares following the entry listed as zero.

Aquestive Therapeutics, Inc. filed a Form 3 for Chief Legal Officer Thomas A. Zalewski.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. filed a Form 3 for Chief Legal Officer Thomas A. Zalewski. The filing lists a holding entry in common stock, with total common shares beneficially owned directly reported as 0 following the reported entry.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zalewski Thomas A.

Role Chief Legal Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct)

Key Figures

Common stock beneficially owned: 0 shares

1 metrics

Common stock beneficially owned 0 shares Total shares following reported holding entry

Key Terms

Common Stock, Chief Legal Officer, direct ownership

3 terms

Common Stock financial

"security_title: "Common Stock" for the reported holding entry"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Chief Legal Officer financial

"officer_title: "Chief Legal Officer" for reporting person Zalewski"

A chief legal officer is a senior executive responsible for overseeing a company's legal matters, ensuring that its activities comply with laws and regulations. They act like a company's legal guide, helping to prevent legal problems and manage risks. For investors, understanding this role is important because it reflects how well a company manages legal risks that could impact its stability and reputation.

direct ownership financial

"ownership_type: "direct" with ownership_code "D" for the holding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Aquestive Therapeutics (AQST) Form 3 show for Thomas A. Zalewski?

The Form 3 shows Chief Legal Officer Thomas A. Zalewski as a reporting person at Aquestive Therapeutics, Inc.. It reports a holding entry in common stock with 0 shares beneficially owned directly following the reported entry.

How many Aquestive Therapeutics (AQST) common shares does the CLO report on Form 3?

The filing reports that Chief Legal Officer Thomas A. Zalewski beneficially owns 0 shares of Common Stock directly following the reported holding entry. No purchase, sale, acquisition, or disposition amounts are shown in this data.

Does the AQST Form 3 indicate any insider buying or selling activity?

No explicit buying or selling activity appears in the provided data. The Form 3 reflects a holding entry with transaction direction marked as unknown and total common stock owned directly reported as 0 shares after the entry.

What ownership type is reported for the AQST Chief Legal Officer on Form 3?

The Form 3 data classifies Chief Legal Officer Thomas A. Zalewski as holding direct ownership, using ownership code D. Following the reported holding entry, direct beneficial ownership in common stock is listed as 0 shares.

Are there any derivative securities reported for AQST’s Chief Legal Officer on Form 3?

The derivative section for this Form 3 is empty. The derivativeSummary shows no derivative positions, and the only security title reported in the provided data is Common Stock with total shares following the entry listed as zero.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/10/2026 - 09:56 AM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zalewski Thomas A.

(Last)

(First)

(Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN

NEW JERSEY

07059

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/02/2026

3. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

	/s/ Hillary T. Yegen, as Attorney-in-Fact for Thomas Zalewski	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR